RecruitingPhase 3NCT06284122
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Lymphoma Academic Research Organisation
- Principal Investigator
- Franck MORSCHHAUSERLymphoma Study Association
- Intervention
- Mosunetuzumab(drug)
- Enrollment
- 790 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2034
Study locations (30)
- AZ SINT-JAN BRUGGE - OOSTENDE AV - Service Hématologie, Bruges, Belgium
- INSTITUT JULES BORDET - Service Hématologie, Brussels, Belgium
- UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie, Brussels, Belgium
- GRAND HOPITAL DE CHARLEROI - Service Hématologie, Charleroi, Belgium
- UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie, Ghent, Belgium
- CHU DE LIEGE - Service Hématologie, Liège, Belgium
- CHR VERVIERS - LA TOURELLE - Service Hématologie, Verviers, Belgium
- CHU UCL NAMUR - SITE GODINNE - Service Hématologie, Yvoir, Belgium
- CH d'AVIGNON - HOPITAL HENRI DUFFAUT - Service d'Onco-Hématologie, Avignon, France
- CH DE LA COTE BASQUE - Service Hématologie, Bayonne, France
- CHU JEAN MINJOZ - Service Hématologie, Besançon, France
- INSTITUT BERGONIE - Service d'Oncologie Médicale, Bordeaux, France
- CENTRE HOSPITALIER JEAN ROUGIER - Service d'Oncologie - Hématologie, Cahors, France
- CH METROPOLE SAVOIE - SITE CHAMBERY - Service Hématologie, Chambéry, France
- CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique, Clermont-Ferrand, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Lymphoma Study Association · Swiss Cancer Institute · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06284122 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca